Therapeutic effect of combining dasatinib and anti-OX40 antibody. Mice received daily gavage of vehicle or dasatinib (150 mg/kg) on day 8-10 and IP injection of IgG control antibody or anti-OX40 antibody (200 μg/mice) on day 10 and 13. (A) Schema of treatment. (B) Tumor sizes of mice for 4 different groups (vehicle + IgG vs dasatinib + anti-OX40: ***P < .0001, dasatinib + IgG vs dasatinib + anti-OX40: **P = .0042, vehicle + anti-OX40 vs dasatinib + anti-OX40: *P = .0257). (C) Kaplan-Meier survival curve of the tumor-bearing mice for 3 different groups (vehicle+IgG vs dasatinib + anti-OX40: ***P < .0001, dasatinib + IgG vs dasatinib + anti-OX40: **P = .0074, vehicle + anti-OX40 versus dasatinib + anti-OX40: *P = .0151). (D) Plots represent the tumor size of individual mice for each group. (E) Kaplan-Meier survival curve of the CD4⁺/CD8⁺ T-cell depletion experiment.